On March 17, 2026, Oncolytics Biotech Inc. completed its redomestication process by changing its jurisdiction of incorporation from Alberta to British Columbia. This move was approved by shareholders during a Special Meeting held on January 15, 2026, where at least two-thirds of the votes cast supported the Continuance. The company will continue to operate under the same name and its common shares will remain listed on the Nasdaq under the ticker symbol 'ONCY'. The transition is part of a two-step process, with the second step involving a further change to the State of Nevada expected to be completed by March 31, 2026. The Continuance does not alter the rights of shareholders, as the common shares will continue to be governed by the new Articles of Incorporation and the Business Corporations Act of British Columbia. The company anticipates that this move will enhance its operational flexibility and governance structure, aligning with its strategic objectives for growth and expansion in the biotech sector.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.